@article{dfc8336f397141378667d96bbb41b346,
title = "Focal brain atrophy in gastric bypass patients with cognitive complaints",
abstract = "Recently, we have identified a series of patients presenting with cognitive complaints after gastric bypass, without any identifiable etiology. We aimed to determine if focal brain atrophy could account for the complaints. A retrospective case series was performed to identify patients with cognitive complaints following gastric bypass who had a volumetric MRI. Voxel-based morphometry was used to assess patterns of grey matter loss in all 10 patients identified, compared to 10 age and gender-matched controls. All patients had undergone Roux-en-Y gastric bypass surgery at a median age of 54 (range: 46-64). Cognitive complaints developed at a median age of 57 (52-69). Formal neuropsychometric testing revealed only minor deficits. No nutritional abnormalities were identified. Voxel-based morphometry demonstrated focal thalamic atrophy in the gastric bypass patients when compared to controls. Patients with cognitive complaints after gastric bypass surgery may have focal thalamic brain atrophy that could result in cognitive impairment.",
keywords = "Cognitive impairment, Gastric bypass, Thalamus, Voxel based morphometry",
author = "Jonathan Graff-Radford and Whitwell, {Jennifer L.} and Trenerry, {Max R.} and Ahlskog, {J. Eric} and Jensen, {Michael D.} and Jack, {Clifford R.} and Josephs, {Keith A.}",
note = "Funding Information: Dr. Josephs is funded by NIH R01-DC010367 (PI), R01-AG037491 (PI), R21-AG38736 (Co-I), and the Dana Foundation (PI). Funding Information: Dr. Ahlskog received the Fred Springer Award from the American Parkinson{\textquoteright}s Disease Association; receives royalties from publishing The Parkinson{\textquoteright}s Disease Treatment Book (Oxford University Press, 2005) and Parkinson{\textquoteright}s Disease Treatment Guide for Physicians (Oxford University Press, 2009), Parkinson{\textquoteright}s Disease and Movement Disorders (Humana Press, 2000), and Surgical Treatment of Parkinson{\textquoteright}s Disease and Other Movement Disorders (Humana Press, 2003); has received honoraria for lectures or educational activities not funded by industry; and receives research support from NIH/NINDS [P50 NS 40256-R (Co-I)]. Funding Information: Dr. Jack serves as a consultant for Elan Corporation; and receives research support from Pfizer, Inc., the NIA [R01-AG11378 (PI), P50-AG16574 (Co-I), R21-AG38736 (Co-I), and U01 AG024904-01 (Co-I)], and the Alexander Family Alzheimer{\textquoteright}s Disease Research Professorship of the Mayo Foundation. Funding Information: Dr. Whitwell receives research support from NIH grants R21-AG38736 (PI), R01- DC010367 (Co-I), and R01-AG037491 (Co-I), and the Dana Foundation (Co-I). ",
year = "2011",
month = dec,
doi = "10.1016/j.jocn.2011.07.012",
language = "English (US)",
volume = "18",
pages = "1671--1676",
journal = "Journal of Clinical Neuroscience",
issn = "0967-5868",
publisher = "Churchill Livingstone",
number = "12",
}